D. Boral Capital Reiterates Buy Rating for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $10.00 price target on the medical research company’s stock.

Other analysts have also issued reports about the stock. StockNews.com assumed coverage on shares of Cytosorbents in a report on Saturday. They issued a “hold” rating on the stock. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Cytosorbents currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Price Performance

NASDAQ:CTSO opened at $1.09 on Tuesday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The stock’s fifty day moving average is $1.02 and its two-hundred day moving average is $1.04. The company has a market capitalization of $59.60 million, a P/E ratio of -3.03 and a beta of 0.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new position in Cytosorbents in the 4th quarter valued at about $30,000. Northern Trust Corp grew its holdings in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares in the last quarter. Avenir Corp increased its stake in Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after buying an additional 118,387 shares during the period. Raymond James Financial Inc. acquired a new stake in Cytosorbents during the 4th quarter worth approximately $99,000. Finally, Renaissance Technologies LLC lifted its holdings in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.